Printer Friendly
The Free Library
14,635,740 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Novartis Completes Cash Tender Offer for Eon Labs; Three Eon Directors Resign, Three Novartis Designees Appointed.


LAKE SUCCESS, N.Y. -- Eon Labs, Inc. (Nasdaq: ELAB) today announced that each of Thomas Strungmann, Ph.D., Frank F. Beelitz and Bernhard Hampl, Ph.D. have resigned from Eon's Board of Directors, effective immediately. The resignations followed the completion by Zodnas Acquisition Corp., an indirectly wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
 of Novartis AG Novartis AG

Swiss pharmaceutical company. It was formed through the 1996 merger of two Swiss firms: Ciba (see Ciba-Geigy) and Sandoz, a chemical company with interests in pharmaceuticals, nutrition, and agriculture.
 (NYSE NYSE

See: New York Stock Exchange
: NVS NVS - Non-Volatile Storage ), of its tender offer for the public shares of Eon pursuant to the terms of the previously announced merger agreement, dated as of February 20, 2005, by and among Eon, Zodnas, Novartis AG and Novartis Corporation.

Pursuant to the merger agreement, the remaining members of Eon's Board of Directors unanimously appointed Terrence Barnett, Urs Naegelin, and Andreas Rummelt, who are designees of Novartis, to fill the resulting vacancies on Eon's Board.

Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. For press releases and other company information, visit the Eon Labs, Inc. website at www.eonlabs.com.

Safe Harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 Statement under the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 21, 2005
Words:329
Previous Article:Virage Logic Reports Third-Quarter Fiscal 2005 Results.
Next Article:CVB Financial Corp. Reports Record Second Quarter Results.
Topics:



Related Articles
Eon Labs Introduces Alternative for $300 Million Brand On First Day of Generic Availability.
Eon Labs Receives Approval for Metformin HCl.
Appeals Court Affirms that Eon Labs' Cyclosporine Does Not Infringe Novartis Patent.
Eon Labs Receives Final Approval for Citalopram HBr Tablets and Will Begin Shipping Immediately.
Eon Labs Receives Final Approval for Cilostazol 100mg Tablets and Will Begin Shipping Immediately.
Eon Labs Relocates Corporate Headquarters.
Eon Labs Receives Final Approval for Anagrelide HCl Capsules and Will Begin Shipping Immediately.
Eon Labs Schedules First Quarter 2005 Results Release and Conference Call for April 28.
Eon Labs Reports Sales and Net Income for the First Quarter of 2005.
2005 was the Year that Mergers and Acquisitions Returned to BioPharma Dealmaking, with Over 230 M&A Transactions.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles